The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer

Abstract Objective Kirsten rat sarcoma viral oncogene homolog (KRAS) is an important driver gene of non‐small cell lung cancer (NSCLC). Despite a rapid progress achieved in the targeted therapy, chemotherapy remains the standard treatment option for patients with KRAS‐mutant NSCLC. This study aimed...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hanxiao Chen, Dingzhi Huang, Gen Lin, Xue Yang, Minglei Zhuo, Yujia Chi, Xiaoyu Zhai, Bo Jia, Jingjing Wang, Yuyan Wang, Jianjie Li, Tongtong An, Meina Wu, Ziping Wang, Jun Zhao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2022-10-01
coleção:	Cancer Medicine
Assuntos:	efficacy KRAS mutation NSCLC prevalence treatme
Acesso em linha:	https://doi.org/10.1002/cam4.4739
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!